SCHEMBL29909253

SCHEMBL29909253

CCN(c1ccccc1)c1nc(Cl)nc2cc(F)c(F)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.43
CSF1R P07333 2/20 0.43
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM1A O60341 1/20 0.38
PDGFRB P09619 1/20 0.37
KDR P35968 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
GBA1 P04062 1/20 0.36
MAPT P10636 2/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
APAF1 O14727 1/20 0.36
CASP3 P42574 1/20 0.36
CASP6 P55212 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23576765 1.00 EGFR (0.43) EGFRCSF1RALDH1A1TDP1KDM1A
SCHEMBL3122164 0.83 EGFR (0.51) EGFRCSF1RALDH1A1TDP1PDGFRB
SCHEMBL30960992 0.83 EGFR (0.51) EGFRCSF1RALDH1A1TDP1PDGFRB
SCHEMBL23577200 0.82 EGFR (0.54) EGFRCSF1RKDM1APDGFRBKDR
SCHEMBL30014070 0.82 EGFR (0.54) EGFRCSF1RKDM1APDGFRBKDR
SCHEMBL23576853 0.82 EGFR (0.32) EGFRCSF1RFABP4FABP5SMN1; SMN2
SCHEMBL23576846 0.81 EGFR (0.41) EGFRCSF1RKDM1AMAPTCRHBP
SCHEMBL30013703 0.81 EGFR (0.41) EGFRCSF1RKDM1AMAPTCRHBP
SCHEMBL30961063 0.81 RXFP1 (0.40) EGFRCSF1RALDH1A1TDP1PDGFRB
SCHEMBL23576711 0.81 RXFP1 (0.40) EGFRCSF1RALDH1A1TDP1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
CN-115362003-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2022-11-18 CN disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK EGFR 1239/4885CSF1R 2614/4885ALDH1A1 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.